secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001104659-23-028690
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion's CLEAR Outcomes trial shows NEXLETOL reduces CV risk 13-23% in statin-intolerant patients
--------------------------------------------------------------------------------

- NEXLETOL reduced MACE-4 by 13% (p=0.004), MACE-3 by 15% (p=0.006), heart attack by 23% (p=0.002), and coronary revascularization by 19% (p=0.001) vs placebo.
- First LDL-C lowering therapy since statins to reduce hard ischemic events in both primary and secondary prevention patients.
- Regulatory filings to FDA and EMA expected in 1H 2023; potential partner milestone payments up to $440M ($300M EU label, $140M other milestones).
- Full-year 2023 operating expenses guided at $225M-$245M, including $25M non-cash stock compensation.
- Results published in NEJM and presented at ACC.23/WCC; conference call scheduled for March 6, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923028690/0001104659-23-028690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923028690/tm238559d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-028690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer